No Data
No Data
Coya Therapeutics Is Maintained at Buy by Chardan Capital
BTIG Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $15
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target
Express News | Coya Therapeutics Inc - Monthly Ld Il-2 Shows Significant Reduction in Ccl2 and Il-15, Increase in Il-4
Express News | Coya Therapeutics Inc - Reports Significant Improvement in Inflammatory Markers in Alzheimer's Patients